Pyxis Oncology, Inc. (PYXS)
Pyxis Oncology, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies to treat cancers.
Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody, which is in Phase 1 clinical trial for the treatment of solid tumors, including non-small cell lung cancer (NSCLC) without driver mutations/translocations, breast cancer, endometrial cancer, thyroid cancer, kidney cancer, cholangiocarcinoma, bladder cancer, colorectal cancer, and head and neck squamous cell carcinoma.
The company's antibody drug conjugate product candidate is PYX-201, an investigational human immunoglobulin G1 isotype site-specifically conjugated, which is in Phase 1 clinical trial for solid tumors, including NSCLC, hormone receptor-positive breast cancer, ovarian cancer, thyroid cancer, pancreatic ductal adenocarcinoma, soft tissue sarcoma, hepatocellular carcinoma, and kidney cancer.
The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
|IPO Date||Oct 1, 2021|
|CEO||Dr. Lara S. Sullivan M.D., MBA|
321 Harrison Avenue
Boston, Massachusetts 02118
|Fiscal Year||January - December|
|John L. Flavin M.B.A., MBA, Ph.D.||Co-Founder and Independent Chairman|
|Dr. Lara S. Sullivan M.D., MBA||Chief Executive Officer, President and Director|
|Pamela Yanchik Connealy M.B.A.||Chief Financial Officer|
|Dr. Jay M. Feingold M.D., Ph.D.||Chief Medical Officer|
|Jitendra Wadhane||Chief Accounting Officer, Senior Vice President of Finance and Corporate Controller|
|Dr. Balu N. Balasubramanian Ph.D.||Interim Chief Technology Officer|
|Dr. Jan Pinkas Ph.D.||Chief Scientific Officer|
|Martina Molsbergen B.S.||Interim Chief Business Officer|
|Dr. Charles T. Gombar Ph.D.||Senior Vice President of Portfolio and Program Management|
Latest SEC Filings
|Nov 28, 2023||8-K||Current Report|
|Nov 7, 2023||10-Q||Quarterly Report|
|Nov 7, 2023||8-K||Current Report|
|Oct 27, 2023||8-K/A||[Amend] Current report|
|Sep 18, 2023||144||Filing|
|Sep 14, 2023||144||Filing|
|Sep 13, 2023||144||Filing|
|Sep 12, 2023||144||Filing|
|Sep 11, 2023||144||Filing|
|Sep 5, 2023||144||Filing|